Golden State Equity Partners Grows Position in Haleon plc (NYSE:HLN)

Golden State Equity Partners grew its holdings in Haleon plc (NYSE:HLN) by 342.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,633 shares of the company’s stock after acquiring an additional 12,877 shares during the period. Golden State Equity Partners’ holdings in Haleon were worth $159,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Fortitude Family Office LLC purchased a new position in shares of Haleon in the third quarter valued at about $28,000. Versant Capital Management Inc increased its holdings in shares of Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the last quarter. Toronto Dominion Bank increased its holdings in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Haleon in the fourth quarter worth about $35,000. Finally, Spire Wealth Management bought a new stake in shares of Haleon in the fourth quarter worth about $39,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Trading Up 0.6 %

Shares of NYSE HLN opened at $9.54 on Wednesday. The business’s 50 day moving average is $9.54 and its two-hundred day moving average is $9.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The stock has a market capitalization of $43.16 billion, a P/E ratio of 28.04, a PEG ratio of 2.69 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon currently has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.